News | November 13, 2024
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
This product will be manufactured at Lupin’s Nagpur facility in India
The company uses iPS cells to develop treatments for diseases relating to the kidney
US Generics grew 5% to Rs. 467 Crores for the quarter
Subscribe To Our Newsletter & Stay Updated
